Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
8.01
+0.27 (3.49%)
At close: Jan 17, 2025, 4:00 PM
8.04
+0.03 (0.37%)
After-hours: Jan 17, 2025, 4:49 PM EST
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 300 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
300
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$734,537
Profits / Employee
-$75,173
Market Cap
1.15B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
AUPH News
- 2 months ago - Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
- 2 months ago - Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - Business Wire
- 2 months ago - Aurinia to Participate in Jefferies London Healthcare Conference - Business Wire
- 2 months ago - Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon - Seeking Alpha
- 2 months ago - Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Business Wire
- 2 months ago - Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - Business Wire
- 2 months ago - Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - Business Wire